Zydus Launches First Kadcyla Biosimilar in India At Sharp Discount
Another In Works From Hetero
Zydus Cadila’s launch of the world’s first biosimilar to Roche’s breast cancer drug Kadcyla in India at an 80% discount to the original's listed price is expected to improve access, and follows its pioneering launch of an adalimumab biosimilar and a NASH therapy
You may also be interested in...
Zydus Cadila sees 40-50% growth continuing in its biosimilars business, with plans for launches in Latin America. Its Kadcyla biosimilar is faring well and after helping the company gain the top spot in India, could also move to clinical trials in the US.
Unless Pfizer or Moderna beat the company to it, Zydus Cadila’s COVID-19 vaccine candidate could be India’s first such jab approved for children. With superior thermostability and proposed economical pricing, it will be one to watch, though a three-dose regimen could be a dampener. Meanwhile, saroglitazar sees slow progress.
Following their original March 2019 tie-up for an oncology antibody-drug conjugate, Daiichi Sankyo and AstraZeneca have entered into a new global deal worth up to $6bn for a second novel asset from the Japanese firm, with potential in breast, lung and other cancers.